# Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer

> **NCT06493240** · PHASE2 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 30 (actual)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **RADIATION:** radiation
- **DRUG:** PD-1 Monoclonal Antibody
- **PROCEDURE:** TME surgery

## Key facts

- **NCT ID:** NCT06493240
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06493240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06493240, "Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06493240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*